Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 6/20 | 0.40 |
| ▸ | METTL3 | Q86U44 | 8/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23530871 | 0.92 | RAB9A (0.39) | KLKB1METTL3MAPTKDM4EPOLB | |
| SCHEMBL23530958 | 0.91 | KLKB1 (0.35) | KLKB1METTL3 | |
| SCHEMBL23530583 | 0.91 | KLKB1 (0.43) | KLKB1METTL3 | |
| SCHEMBL23531012 | 0.88 | KLKB1 (0.34) | KLKB1METTL3MAPTKDM4EALDH1A1 | |
| SCHEMBL23530720 | 0.85 | KLKB1 (0.39) | KLKB1MAPTKDM4E | |
| SCHEMBL23530692 | 0.84 | KLKB1 (0.33) | KLKB1METTL3KDM4EALDH1A1POLB | |
| SCHEMBL23530932 | 0.82 | RBP4 (0.33) | KLKB1METTL3KDM4EALDH1A1 | |
| SCHEMBL23530805 | 0.81 | KDM4E (0.49) | METTL3MAPTKDM4EALDH1A1 | |
| SCHEMBL22413305 | 0.81 | MAPK1 (0.39) | POLB | |
| SCHEMBL23530627 | 0.80 | KLKB1 (0.37) | KLKB1METTL3KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| WO-2021122745-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | CDK1, CDK3, CDK2 | KLKB1 2395/4885METTL3 3227/4885MAPT 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.